Linkedin Instagram

WES trio or WGS solo?

When the key variable is not the size of the test

Many children referred for genomic testing have already gone through a long diagnostic pathway.

Developmental delay.
Autism spectrum disorder.
Epilepsy.
Language regression.
Hypotonia.
Unexplained neurological findings.

By the time genomic sequencing is discussed, multiple evaluations are often already available:

MRI scans.
Metabolic investigations.
Targeted genetic tests.
Gene panels.

In some cases, → Whole Genome Sequencing (WGS) is proposed immediately, based on the assumption that broader sequencing will necessarily produce better answers.

But in pediatric genomics, the decisive factor is not always how much DNA is sequenced.

Sometimes, the critical variable is whether the genomic data can be interpreted within a structured familial context.

This is one of the reasons why → TRIO Whole exome sequencing (WES trio) often remains one of the most informative first-line approaches in pediatric rare disease diagnostics.

In these situations, the difference does not lie in performing the test.

It lies in how the test is done from the beginning.

→ If this situation feels familiar, start the diagnostic pathway here.

Why broader sequencing does not always mean higher diagnostic efficiency

→ Whole Genome Sequencing (WGS) analyzes a broader portion of the patient’s DNA than → Whole Exome Sequencing (WES).

This broader coverage may increase the possibility of identifying:

  • structural variants
  • deep intronic changes
  • non-coding pathogenic mechanisms
  • repeat expansions
  • genomic alterations not routinely captured by exome sequencing

For this reason, WGS is often perceived as the most comprehensive genomic test currently available.

However, in clinical practice, the additional detection potential of WGS does not automatically translate into a higher probability of reaching a diagnosis rapidly.

Many of the genomic alterations theoretically detectable through WGS still require:

  • dedicated bioinformatic pipelines
  • multiple CNV and structural variant calling systems
  • RNA-based studies
  • functional validation
  • finer techniques to define the exact number of repeat expansions (where even ±1 repeat may change the diagnosis)
  • or additional confirmation technologies that are not routinely available in standard diagnostic settings.

 

As a result, broader sequencing alone does not necessarily produce faster or more definitive clinical answers.

In pediatric rare disease diagnostics, the challenge is often not simply detecting genomic variation, but understanding its biological context — including whether the identified variants are inherited or arose de novo.

For this reason, diagnostic efficiency is not determined only by how much of the genome is sequenced.

It also depends on how effectively the genomic data can be interpreted from the beginning.

Why parental genomic context changes interpretation

One of the main advantages of TRIO Whole Exome Sequencing (WES trio) is not simply the addition of two extra samples.

It is the possibility of interpreting the patient’s genomic data within a defined familial structure.

Very importantly, the presence of parental data also helps:

  • automatically confirm variants among trio members, helping include or exclude variants showing borderline quality signals
  • reduce interpretative noise by excluding variants whose inheritance pattern makes them unlikely to be pathogenic
  • let de novo pathogenic variants immediately emerge from the analysis

 

In selected prenatal cases, when maternal cell contamination (MCC) studies are not available, parental genomic context may also help identify or exclude possible maternal contamination patterns during interpretation.

For this reason, the diagnostic advantage of WES trio does not depend only on sequencing technology.

It also derives from the biological structure surrounding the genomic data from the beginning.

.

Situations where WGS may offer additional value

Initially, the distinction between Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) appeared to depend mainly on the type of disease involved.

However, the increasing identification of structural variants, other non-coding pathogenic mechanisms such as variants involving regulatory enhancers, and, most importantly, deep intronic variants, suggests a far more complex reality than initially expected.

Variants of this type have now been reported across several different categories of genetic disorders, including:

  • inherited retinal diseases
  • hearing loss
  • developmental disorders
  • NF1
  • metabolic diseases
  • and even syndromic developmental conditions such as Sotos syndrome and Cornelia de Lange syndrome.

 

As a result, the question becomes less:

“Which disease requires WGS?”

and more:

“Which testing structure maximizes the probability of obtaining a clinically meaningful answer early in the diagnostic process?”

At the same time, WGS may provide additional value in selected unresolved cases, particularly when:

  1. non-coding pathogenic mechanisms are strongly suspected — although, at present, this scenario is represented mainly by selected conditions such as inherited retinal dystrophies
  2. previous Whole Exome Sequencing (WES) has remained negative despite strong clinical suspicion
  3. complex structural rearrangements are considered plausible, beyond the simpler and more frequent copy number variants usually detectable through exome sequencing
  4. adult-onset neurological or metabolic disorders, which may present with borderline clinical manifestations or subtle biochemical abnormalities, and where parental samples may be difficult to include in the diagnostic process.

Choosing the right first-line strategy

In many pediatric rare disease settings, two major factors continue to favor TRIO WES as a first-line strategy.

First, despite the growing importance of non-coding mechanisms, most currently identified pathogenic variants still remain located within the coding regions analyzed through → Whole Exome Sequencing (WES).

Second, the presence of parental genomic context immediately provides inheritance information that may substantially simplify interpretation.

Last but not least, from a budget perspective, WES trio also eliminates the need for additional parental carrier testing later in the diagnostic process.

By contrast, after WGS solo, parental segregation studies may still become necessary, sometimes generating significant additional costs — even when only a small number of variants ultimately require clarification.

For these reasons, WES trio continues to represent one of the most effective and sustainable first-line diagnostic structures in many pediatric neurological and developmental disorders.


Once these limitations and interpretative challenges are clearly understood, it also becomes evident that WGS still represents the broadest currently available genomic diagnostic approach — particularly when performed as WGS trio.

Its ability to explore coding and non-coding regions simultaneously makes it, from a purely technical perspective, the most comprehensive sequencing strategy currently available for genetic disease diagnostics.

However, broader sequencing alone does not automatically guarantee the fastest, simplest, or most interpretable diagnostic pathway in every clinical setting.

Once these limitations and interpretative challenges are clearly understood, it also becomes evident that WGS still represents the broadest currently available genomic diagnostic approach — particularly when performed as WGS trio.

Its ability to explore coding and non-coding regions simultaneously makes it, from a purely technical perspective, the most comprehensive sequencing strategy currently available for genetic disease diagnostics, as well as the strongest substrate for future clinical reinterpretation when needed.

However, if not performed in trio, broader sequencing alone does not automatically guarantee the fastest, simplest, or most interpretable diagnostic pathway in every clinical setting.

START THE DIAGNOSTIC PATHWAY
DISCUSS A CLINICAL CASE